Nordy triggered a differentiation program on glioma stem-like cells (GSLCs) towards an astrocytic phenotype that reduced the frequency of GSCs, and inhibited the growth of xenografted glioma cells by inhibiting the activity of Alox-5. Here, ALOX5 is linked to central nervous system cancer.